The FDA approved nivolumab (Opdivo, Bristol Myers Squibb) for the adjuvant treatment of completely resected stage IIB/C melanoma in patients aged 12 years and older.
Efficacy was evaluated in CheckMate 76K, a randomized, double-blind trial enrolling 790 patients with stage IIB/C melanoma. Patients were randomized (2:1) to nivolumab 480 mg or placebo by IV infusion every four weeks for up to one year or until disease recurrence or unacceptable toxicity.
Enrollment required complete resection of
OCTOBER 17, 2023